Relationship of HIF‑1α expression with apoptosis and cell cycle in bone marrow mesenchymal stem cells from patients with myelodysplastic syndrome

Qu,Beibei; Han,Xiuhua; Zhao,Lan; Zhang,Feifei; Gao,Qingmei

doi:10.3892/mmr.2022.12755

Relationship of HIF‑1α expression with apoptosis and cell cycle in bone marrow mesenchymal stem cells from patients with myelodysplastic syndrome

Authors:
- Beibei Qu
- Xiuhua Han
- Lan Zhao
- Feifei Zhang
- Qingmei Gao
View Affiliations

Affiliations: Department of Hematology, Jiading District Central Hospital, Affiliated Shanghai University of Medicine and Health Sciences, Shanghai 201800, P.R. China, Department of Hematology, Jiading District Central Hospital, Affiliated Shanghai University of Medicine and Health Sciences, Shanghai 201800, P.R. China
Published online on: May 30, 2022 https://doi.org/10.3892/mmr.2022.12755
Article Number: 239
Copyright: © Qu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myelodysplastic syndrome (MDS) is a group of abnormal clonal disorders with ineffective hematopoiesis, which are incurable with conventional therapy. Of note, MDS features an abnormal bone marrow microenvironment, which is related to its incidence. The hypoxia‑inducible factor‑1α (HIF‑1α) transcriptional signature is generally activated in bone marrow stem/progenitor cells of patients with MDS. To analyze the expression of HIF‑1α in bone marrow mesenchymal stem cells (BM‑MSCs) and the apoptosis and cell cycle features associated with the disease, BM‑MSCs were obtained from 40 patients with a definitive diagnosis of MDS and 20 subjects with hemocytopenia but a negative diagnosis of MDS as a control group. Reverse transcription‑quantitative PCR and western blot analyses were used to measure HIF‑1α expression in cells from the two groups and apoptosis and cell cycle were also analyzed and compared between the groups using flow cytometry assays. BM‑MSCs from both the control group and the MDS group exhibited a fibroblast‑like morphology, had similar growth cycles and were difficult to passage stably. It was observed that BM‑MSCs from the MDS group had significantly higher HIF‑1α expression levels than the control group (P<0.05). Furthermore, the BM‑MSCs from the MDS group had a higher proportion of cells in early apoptosis (5.22±1.34 vs. 2.04±0.08%; P<0.0001) and late apoptosis (3.38±0.43 vs. 1.23±0.11%; P<0.01) and exhibited cell cycle arrest. This may be a noteworthy aspect of the pathogenesis of MDS and may be related to high HIF‑1α expression under a hypoxic state in the bone marrow microenvironment. Furthermore, the expression of HIF‑1α in bone marrow tissue sections from patients with MDS in the International Prognostic Scoring System (IPSS) lower‑risk group was higher than that from patients with MDS in the IPSS high‑risk group. These results revealed the role of HIF‑1α as a central pathobiology mediator of MDS and an effective therapeutic target for a broad spectrum of patients with MDS, particularly for patients in the lower‑risk group.

View Figures

View References

1	Platzbecker U, Kubasch AS, Homer-Bouthiette C and Prebet T: Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 35:2182–2198. 2021. View Article : Google Scholar
2	Adès L, Itzykson R and Fenaux P: Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar
3	Raaijmakers MH: Myelodysplastic syndromes: Revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int J Hematol. 95:17–25. 2012. View Article : Google Scholar
4	Ishibashi M, Tamura H and Ogata K: Disease progression mechanism in myelodysplastic syndromes: Insight into the role of the microenvironment. Leuk Res. 35:1449–1452. 2011. View Article : Google Scholar : PubMed/NCBI
5	Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, Lier A, Eisen C, Nowak V, Zens B, et al: Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 14:824–837. 2014. View Article : Google Scholar
6	Balderman SR, Li AJ, Hoffman CM, Frisch BJ, Goodman AN, LaMere MW, Georger MA, Evans AG, Liesveld JL, Becker MW and Calvi LM: Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome. Blood. 127:616–625. 2016. View Article : Google Scholar : PubMed/NCBI
7	Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, et al: Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 464:852–857. 2010. View Article : Google Scholar : PubMed/NCBI
8	Roela RA, Carraro DM, Brentani HP, Kaiano JH, Simão DF, Guarnieiro R, Lopes LF, Borojevic R and Brentani MM: Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes. Leuk Res. 31:579–589. 2007. View Article : Google Scholar : PubMed/NCBI
9	Corradi G, Baldazzi C, Očadlíková D, Marconi G, Parisi S, Testoni N, Finelli C, Cavo M, Curti A and Ciciarello M: Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to suppotr leukemia cell survival. Stem Cell Res Ther. 9:2712018. View Article : Google Scholar : PubMed/NCBI
10	Frolova O, Samudio I, Benito JM, Jacamo R, Kornblau SM, Markovic A, Schober W, Lu H, Qiu YH, Buglio D, et al: Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 13:858–870. 2012. View Article : Google Scholar : PubMed/NCBI
11	Albadari N, Deng S and Li W: The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov. 14:667–682. 2019. View Article : Google Scholar : PubMed/NCBI
12	Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M and Uemura H: Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24⁺ patients with renal cell carcinoma. Int Immunopharmacol. 44:197–202. 2017. View Article : Google Scholar
13	Lotfinia M, Lak S, Mohammadi Ghahhari N, Johari B, Maghsood F, Parsania S, Sadegh Tabrizi B and Kadivar M: Hypoxia Pre-Conditioned embryonic mesenchymal stem cell secretome reduces IL-10 production by peripheral blood mononuclear cells. Iran Biomed J. 21:24–31. 2017. View Article : Google Scholar : PubMed/NCBI
14	Hayashi Y, Zhang Y, Yokota A, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, et al: Pathobiological pseudohypoxia as a putative mechanism underlying myelodysplastic syndromes. Cancer Discov. 8:1438–1457. 2018. View Article : Google Scholar : PubMed/NCBI
15	Hayashi Y: Role of HIF1A in the development of myelodysplastic syndromes. Rinsho Ketsueki. 60:818–823. 2019.(In Japanese).
16	Ma CP, Liu H, Yi-Feng Chang I, Wang WC, Chen YT, Wu SM, Chen HW, Kuo YP, Shih CT, Li CY and Tan BC: ADAR1 promotes robust hypoxia signaling via distinct regulation of multiple HIF-1α-inhibiting factors. EMBO Rep. 20:e471072019. View Article : Google Scholar : PubMed/NCBI
17	Lee JH, Yoon YM and Lee SH: Hypoxic preconditioning promotes the bioactivities of mesenchymal stem cells via the HIF-1α-GRP78-Akt Axis. Int J Mol Sci. 18:13202017. View Article : Google Scholar
18	Chen T, Zhu H, Wang Y, Zhao P, Chen J, Sun J, Zhang X and Zhu G: Apoptosis of bone marrow mesenchymal stromal/stem cells via the MAPK and endoplasmic reticulum stress signaling pathways. Am J Transl Res. 10:2555–2566. 2018.PubMed/NCBI
19	Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, et al: Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 93:1245–1253. 2018. View Article : Google Scholar
20	Garcia-Manero G: Myelodysplasic syndromes: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 86:490–498. 2011. View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Flores-Figueroa E, Varma S, Montgomery K, Greenberg PL and Gratzinger D: Distinctive contact between CD34⁺ hematopoietic progenitors and CXCL12⁺ CD271⁺ mesenchymal stromal cells in benign and myelodysplastic bone marrow. Lab Invest. 92:1330–1341. 2012. View Article : Google Scholar
23	Purwaningrum M, Jamilah NS, Purbantoro SD, Sawangmake C and Nantavisai S: Comparative characteristic study from bone marrow-derived mesenchymal stem cells. J Vet Sci. 22:e742021. View Article : Google Scholar
24	Busser H, Najar M, Raicevic G, Pieters K, Velez Pombo R, Philippart P, Meuleman N, Bron D and Lagneaux L: Isolation and characterization of human mesenchymal stromal cells subpopulations: Comparison of bone marrow and adipose tissue. Stem Cells Dev. 24:2142–2157. 2015. View Article : Google Scholar : PubMed/NCBI
25	Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International society for cellular therapy position statement. Cytotherapy. 8:315–317. 2006. View Article : Google Scholar : PubMed/NCBI
26	Cicione C, Muiños-López E, Hermida-Gómez T, Fuentes-Boquete I, Díaz-Prado S and Blanco FJ: Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential. Stem Cells Int. 2013:2328962013. View Article : Google Scholar
27	Guang FR, Ling Z, Huang JS, Huang WX, Gong BD, Fang XX, Zhang XY and Tang JP: Effect of mesenchymal stem cells on Sjögren-like mice and the microRNA expression profiles of splenic CD4⁺ T cells. Exp Ther Med. 13:2828–2838. 2017. View Article : Google Scholar : PubMed/NCBI
28	Johnson RC, Kurzer JH, Greenberg PL and Gratzinger D: Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival. Am J Clin Pathol. 142:795–802. 2014. View Article : Google Scholar
29	Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, et al: Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: A phase II Study by the Groupe Francophone des Myelodysplasies (GFM). J Clin Oncol. 39:1575–1583. 2021. View Article : Google Scholar
30	Gars E, Yousry SM, Babu D, Kurzer JH, George TI and Gratzinger D: A replicable CD271⁺ mesenchymal stromal cell density score: Bringing the dysfunctional myelodysplastic syndrome niche to the diagnostic laboratory. Leuk Lymphoma. 58:1730–1732. 2017. View Article : Google Scholar
31	Ohnishi S, Yasuda T, Kitamura S and Nagaya N: Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells. 25:1166–1177. 2007. View Article : Google Scholar : PubMed/NCBI
32	Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S and Shahrara S: The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 18:433–448. 2015. View Article : Google Scholar : PubMed/NCBI
33	Alonso D, Serrano E, Bermejo FJ and Corral RS: HIF-1α-regulated MIF activation and Nox2-dependent ROS generation promote Leishmania amazonensis killing by macrophages under hypoxia. Cell Immunol. 335:15–21. 2019. View Article : Google Scholar
34	Abdul-Aziz AM, Shafat MS, Mehta TK, Di Palma F, Lawes MJ, Rushworth SA and Bowles KM: MIF-Induced Stromal PKCβ/IL8 is essential in human acute myeloid Leukemia. Cancer Res. 77:303–311. 2017. View Article : Google Scholar : PubMed/NCBI
35	Mangano K, Mazzon E, Basile MS, Di Marco R, Bramanti P, Mammana S, Petralia MC, Fagone P and Nicoletti F: Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget. 9:17951–17970. 2018. View Article : Google Scholar
36	Xu S, Guo X, Gao X, Xue H, Zhang J, Guo X, Qiu W, Zhang P and Li G: Macrophage migration inhibitory factor enhances autophagy by regulating ROCK1 activity and contributes to the escape of dendritic cell surveillance in glioblastoma. Int J Oncol. 49:2105–2115. 2016. View Article : Google Scholar
37	Presti M, Mazzon E, Basile MS, Petralia MC, Bramanti A, Colletti G, Bramanti P, Nicoletti F and Fagone P: Overexpression of macrophage migration inhibitory factor and functionally-related genes, D-DT, CD74, CD44, CXCR2 and CXCR4, in glioblastoma. Oncol Lett. 16:2881–2886. 2018.
38	Cavalli E, Ciurleo R, Petralia MC, Fagone P, Bella R, Mangano K, Nicoletti F, Bramanti P and Basile MS: Emerging role of the macrophage migration inhibitory factor family of cytokines in neuroblastoma. Pathogenic effectors and novel therapeutic targets? Molecules. 25:11942020.
39	Soumoy L, Kindt N, Ghanem G, Saussez S and Journe F: Role of macrophage migration inhibitory factor (MIF) in melanoma. Cancers (Basel). 11:5292019. View Article : Google Scholar
40	Falantes JF, Trujillo P, Piruat JI, Calderón C, Márquez-Malaver FJ, Martín-Antonio B, Millán A, Gómez M, González J, Martino ML, et al: Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 15:236–244. 2015. View Article : Google Scholar : PubMed/NCBI
41	Stergiou IE, Kambas K, Poulaki A, Giannouli S, Katsila T, Dimitrakopoulou A, Vidali V, Mouchtouris V, Kloukina I, Xingi E, et al: Exploiting the role of hypoxia-inducible factor 1 and pseudohypoxia in the myelodysplastic syndrome pathophysiology. Int J Mol Sci. 22:40992021. View Article : Google Scholar
42	Tong H, Hu C, Zhuang Z, Wang L and Jin J: Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes. Leuk Lymphoma. 53:2412–2418. 2012. View Article : Google Scholar
43	Liu Z, Tian M, Ding K, Liu H, Wang Y and Fu R: High expression of PIM2 induces HSC proliferation in myelodysplastic syndromes via the IDH1/HIF1-α signaling pathway. Oncol Lett. 17:5395–5402. 2019.
44	Pleyer L, Valent P and Greil R: Mesenchymal stem and progenitor cells in normal and dysplastic hematopoiesis-masters of survival and clonality? Int J Mol Sci. 17:10092016. View Article : Google Scholar
45	Blau O, Baldus CD, Hofmann WK, Thiel G, Nolte F, Burmeister T, Türkmen S, Benlasfer O, Schümann E, Sindram A, et al: Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood. 118:5583–5592. 2011. View Article : Google Scholar : PubMed/NCBI
46	Wang H, Niu H, Zhang T, Xing L, Shao Z and Fu R: Low- and intermediate-risk myelodysplastic syndrome with pure red cell aplasia. Hematology. 26:444–446. 2021. View Article : Google Scholar : PubMed/NCBI
47	Sato F, Miyaoka Y, Miyajima A and Tanaka M: Oncostatin M maintains the hematopoietic microenvironment in the bone marrow by modulating adipogenesis and osteogenesis. PLoS One. 9:e1162092014. View Article : Google Scholar : PubMed/NCBI
48	Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B and Hellstrom-Lindberg E: Granulocyte colony-stimulating factor inhibits spontaneous cytochrome C release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood. 101:1080–1086. 2003. View Article : Google Scholar : PubMed/NCBI
49	Ferrer RA, Wobus M, List C, Wehner R, Schönefeldt C, Brocard B, Mohr B, Rauner M, Schmitz M, Stiehler M, et al: Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica. 98:1677–1685. 2013. View Article : Google Scholar
50	Bakhtiari T, Ghaderi A, Safaee Nodehi SR, Aghazadeh Z, Tofighi Zavareh F, Jafarnezhad-Ansariha F, Barati A and Mirshafiey A: An in vitro assessment for evaluating the efficiency of β-d-mannuronic acid (M2000) in myelodysplastic syndrome. J Cell Physiol. 234:12971–12977. 2019. View Article : Google Scholar
51	da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop M, Sandmann S, Dugas M, et al: Clonal evolution in myelodysplastic syndromes. Nat Commun. 8:150992017. View Article : Google Scholar : PubMed/NCBI